Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke

Phase 4

Completed

Conditions: Stroke

Interventions: Drug: Clopidogrel
Drug: Clopidogrel placebo
Drug: Aspirin

First Posted Date: 2008-12-24

Last Posted Date: 2014-02-28

Lead Sponsor: Sanofi

Target Recruit Count: 358

Registration Number: NCT00814268

Locations: 🇰🇷
Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Phase 2

Completed

Conditions: Triple Negative Breast Cancer

Interventions: Drug: gemcitabine plus carboplatin plus BSI-201

First Posted Date: 2008-12-23

Last Posted Date: 2016-03-17

Lead Sponsor: Sanofi

Target Recruit Count: 80

Registration Number: NCT00813956

Locations: 🇺🇸
Stanford Comprehensive Cancer Center, Stanford, California, United States
🇺🇸
PrECOG, Philadelphia, Pennsylvania, United States

Efficacy, Safety, and Tolerability of Nerispirdine in Patients With Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: placebo
Drug: Nerispirdine

First Posted Date: 2008-12-19

Last Posted Date: 2016-02-26

Lead Sponsor: Sanofi

Target Recruit Count: 405

Registration Number: NCT00811902

Locations: 🇳🇴
Sanofi-Aventis Administrative Office, Lysaker, Norway
🇪🇸
Sanofi-aventis Administrative Office, Barcelona, Spain

Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Placebo (for teriflunomide)
Drug: Teriflunomide
Drug: Interferon-β [IFN-β]
Drug: Glatiramer Acetate [GA]

First Posted Date: 2008-12-19

Last Posted Date: 2012-12-31

Lead Sponsor: Sanofi

Target Recruit Count: 182

Registration Number: NCT00811395

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, United Kingdom

Taxotere New Indication - Gastric Cancer Treatment Registration Trial

Phase 3

Completed

Conditions: Stomach Neoplasms

Interventions: Drug: 5-fluorouracil
Drug: Cisplatin
Drug: Docetaxel

First Posted Date: 2008-12-19

Last Posted Date: 2012-08-31

Lead Sponsor: Sanofi

Target Recruit Count: 243

Registration Number: NCT00811447

Locations: 🇨🇳
Sanofi-Aventis Administrative Office, Shanghai, China

Study of Non Inferiority Bi-Profenid® 200mg Versus Bi-Profenid® 300mg Among Patients Presenting of the Post-traumatic or Rheumatologic Acute Affections of the Locomotor Apparatus (BIPROPAIN)

Phase 3

Completed

Conditions: Pain

Interventions: Drug: ketoprofen 100 mg
Drug: ketoprofen

First Posted Date: 2008-12-17

Last Posted Date: 2009-09-25

Lead Sponsor: Sanofi

Target Recruit Count: 409

Registration Number: NCT00810121

Locations: 🇫🇷
Sanofi-Aventis Administrative Office, Paris, France

Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: ZD6474 (Vandetanib)
Radiation: Whole Brain Radiotherapy (WBRT)
Drug: ZD6474

First Posted Date: 2008-12-11

Last Posted Date: 2016-08-29

Lead Sponsor: Sanofi

Target Recruit Count: 5

Registration Number: NCT00807170

Locations: 🇳🇱
Research site, Maastricht, Netherlands

Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties

Phase 3

Completed

Conditions: Primary Insomnia

Interventions: Drug: Eplivanserin
Drug: Placebo

First Posted Date: 2008-12-09

Last Posted Date: 2016-03-07

Lead Sponsor: Sanofi

Target Recruit Count: 637

Registration Number: NCT00805350

Locations: 🇵🇱
Sanofi-Aventis Administrative Office, Warszawa, Poland

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Teriflunomide (HMR1726)

First Posted Date: 2008-12-05

Last Posted Date: 2017-01-30

Lead Sponsor: Sanofi

Target Recruit Count: 742

Registration Number: NCT00803049

Locations: 🇳🇱
Investigational Site Number 4604, Sittard-Geleen, Netherlands
🇺🇦
Investigational Site Number 3505, Ivano-Frankovsk, Ukraine
🇺🇦
Investigational Site Number 3510, Kharkiv, Ukraine

and more 113 locations

Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain

Phase 2

Completed

Conditions: Pain

Interventions: Drug: ataciguat (HMR1766)
Drug: placebo

First Posted Date: 2008-12-01

Last Posted Date: 2011-04-01

Lead Sponsor: Sanofi

Target Recruit Count: 62

Registration Number: NCT00799656

Locations: 🇷🇴
Sanofi-Aventis Administrative Office, Bucuresti, Romania

Home Terms & Conditions Privacy Policy